Quality of life during lanadelumab treatment in patients with hereditary angioedema: 24-month results from the enable study

被引：0
|
作者：
Saguer, I. Martinez [1 ]
Magerl, M. [2 ,3 ]
Andriotti, T. [4 ]
Botha, J. [5 ]
Agmon-Levin, N. [6 ]
Watt, M. [4 ]
Maurer, M. [3 ,7 ]
机构：
[1] HRZM Hemophilia Ctr Rhein Main, Morfelden Walldorf, Germany
[2] Charite Univ Med Berlin, Inst Allergol, Berlin, Germany
[3] Fraunhofer Inst Translat Med & Pharmacol ITMP, Berlin, Germany
[4] Takeda Dev Ctr Amer Inc, Lexington, KY USA
[5] Takeda Pharmaceut Int AG, Zurich, Switzerland
[6] Tel Hashomer Hosp, Ctr Autoimmune Dis, Sheba Med Ctr, Ramat Gan, Israel
[7] Charite Univ Med Berlin, Inst Allergol, Berlin, Germany
来源：
ALLERGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
000902
引用
收藏
页码：26 / 27
页数：2
相关论文
共 50 条
  • [21] Clinical status course and quality of life: 24-month results from the European schizophrenia outpatients health outcomes (SOHO) study
    Haro, JM
    Novick, D
    Belger, M
    Ratcliffe, M
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S496 - S496
  • [22] Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)
    Bente L. Langdahl
    Östen Ljunggren
    Claude-Laurent Benhamou
    Fernando Marin
    George Kapetanos
    Tomaz Kocjan
    Eric Lespessailles
    Nicola Napoli
    Tatjana Nikolic
    Helmut Petto
    Thomas Moll
    Erik Lindh
    Calcified Tissue International, 2016, 99 : 259 - 271
  • [23] Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)
    Langdahl, Bente L.
    Ljunggren, Osten
    Benhamou, Claude-Laurent
    Marin, Fernando
    Kapetanos, George
    Kocjan, Tomaz
    Lespessailles, Eric
    Napoli, Nicola
    Nikolic, Tatjana
    Petto, Helmut
    Moll, Thomas
    Lindh, Erik
    CALCIFIED TISSUE INTERNATIONAL, 2016, 99 (03) : 259 - 271
  • [24] A SURVEY TO DETERMINE TREATMENT PREFERENCES AND QUALITY OF LIFE OF PATIENTS WITH HEREDITARY ANGIOEDEMA
    Diwakar, L.
    Richter, A.
    Huissoon, A.
    Jolles, S.
    El-Shanawany, T.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 143 - 143
  • [25] Direct treatment cost outcomes among patients with medial meniscus deficiency: results from a 24-month surveillance study
    Hershman, Elliott B.
    Jarvis, John L.
    Mick, Travis
    Dushaj, Kristina
    Elsner, Jonathan J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (03) : 427 - 437
  • [26] OBSERVATIONAL STUDY ON THE TREATMENT, COST AND QUALITY OF LIFE OF SUBJECTS WITH HEREDITARY ANGIOEDEMA
    Bouillet, L.
    Montauban, V
    Finck, K.
    Jeanbat, V
    Bouee, S.
    VALUE IN HEALTH, 2011, 14 (07) : A386 - A386
  • [27] Effect of Lanadelumab on Coagulation Parameters in Patients With Hereditary Angioedema: Findings From The Phase 3 HELP Study
    Schmaier, Alvin H.
    Bauer, Kenneth A.
    Cicardi, Marco
    Hebert, Jacques
    Johnston, Douglas T.
    Busse, Paula J.
    Paes, Kim
    Sexton, Daniel J.
    Kenniston, Jon
    Nurse, Christina
    Zaragoza, Rafael H.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB42 - AB42
  • [28] LONG-TERM SAFETY OF LANADELUMAB IN HEREDITARY ANGIOEDEMA (HAE): INTERIM RESULTS FROM THE HELP OLE STUDY
    Johnston, D.
    Banerji, A.
    Nurse, C.
    Lu, P.
    Aygoren-Pursun, E.
    Kiani-Alikhan, S.
    Soteres, D.
    Lugar, P.
    Zuraw, B.
    Lockey, R.
    Schwartz, L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S30 - S30
  • [29] Lanadelumab Effectiveness and Safety in Adolescent Patients With Hereditary Angioedema Aged 12 to <18 Years: Pooled Results From the Real-World ENABLE and EMPOWER Studies
    Tachdjian, Raffi
    Banerji, Aleena
    Busse, Paula
    Agmon-Levin, Nancy
    Anderson, John
    Cancian, Mauro
    Spadaro, Giuseppe
    Enciu, Carmen
    Estepan, Daniel Nova
    Khutoryansky, Natalie
    Recke, Andreas
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB78 - AB78
  • [30] Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies
    Craig, Timothy J.
    Zaragoza-Urdaz, Rafael H.
    Li, H. Henry
    Yu, Ming
    Ren, Hong
    Juethner, Salome
    Anderson, John
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2022, 18 (01):
12345